Form 4: ANAPTYSBIO CLO Sells Shares After Option Exercise

ANAPTYSBIO's Chief Legal Officer, Eric J. Loumeau, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

Summary

• Eric J. Loumeau, Chief Legal Officer of ANAPTYSBIO, INC, reported transactions on September 30, 2025.
• Exercised employee stock options to acquire 5,000 shares of common stock at an exercise price of $14.02 per share.
• Sold 8,240 shares of common stock at a price of $29 per share.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on April 11, 2025.
• Following these transactions, Mr. Loumeau directly beneficially owns 9,088 shares of common stock.
• He also holds remaining options to purchase an aggregate of 490,310 shares of common stock, comprising 68,000 from the exercised grant and 422,310 additional options.
• Beneficial ownership before the sale included 1,325 shares acquired under the Company's ESPP.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there is insider selling, it was conducted under a pre-arranged 10b5-1 plan, which mitigates concerns about opportunistic selling. The exercise of options also indicates a belief in the company's value.

Positives

• Exercise of stock options indicates the executive saw value in the company's stock above the exercise price.
• The transactions were conducted under a pre-arranged 10b5-1 trading plan, suggesting a systematic approach to liquidity rather than a reaction to new, undisclosed negative information.

Negatives

• Insider selling of 8,240 shares, even if planned, can sometimes be perceived negatively by the market.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide information relevant to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may observe the insider selling activity, which could lead to questions about management's confidence, although the 10b5-1 plan mitigates this concern.

Key Dates

Recommendation

The insider transactions, specifically the sale of shares, were conducted under a pre-established 10b5-1 trading plan. This suggests a planned liquidity event for the executive rather than a signal of a negative outlook for the company. While insider selling can sometimes be a bearish signal, the pre-planned nature reduces its immediate interpretative impact. The exercise of options also indicates the executive saw value in the stock. Therefore, based solely on this Form 4, a 'hold' recommendation is appropriate as it does not provide sufficient new information to alter a fundamental investment thesis.

Keywords

ANAPTYSBIO, ANAB, Eric J. Loumeau, Chief Legal Officer, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Equity Sales, Beneficial Ownership